The Pharmaceutical Journal
Vol 279 No 7472 p376
6 October 2007

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Thiazolidinedione safety

Patients with prediabetes or type 2 diabetes given thiazolidinediones (either rosiglitazone or pioglitazone) have an increased risk of developing congestive heart failure but not an increased risk of cardiovascular death, compared with controls, data from a new meta-analysis indicate (Lancet 2007;370:1129).